中國農產品交易(00149.HK)中期營業額約3.22億港元 同比減少約22%
格隆匯11月24日丨中國農產品交易(00149.HK)公吿,截至2022年9月30日止6個月中期業績,集團錄得營業額約3.22億港元,同比減少約22%,此乃由於確認的物業銷售及市場經營營業額均低於2021對應期間。公司擁有人應占期間溢利約800萬港元,而2021對應期間則為約1800萬港元。每股盈利0.08港仙。
於期間,集團主要在中國從事農產品交易市場物業管理及銷售。於期間,新冠肺炎疫情在中國各地反彈,但對集團的業務營運影響輕微,原因為公司市場緊緊遵循地方政府所實施嚴格衞生要求。為應對未來增長,公司一直積極研究及評估多項商機以多元化集團的收入來源併為公司股東帶來長遠利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.